^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD20-targeted CAR-T immunotherapy

    Related drugs:
    23h
    RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas (clinicaltrials.gov)
    P1/2, N=10, Not yet recruiting, Affiliated Hospital of Nantong University
    New P1/2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    2d
    M-2024-424: MB-CART2019.1 in refractory MS (2024-517601-82-00)
    P1/2, N=25, Recruiting, Miltenyi Biomedicine GmbH | Not yet recruiting --> Recruiting
    Enrollment open
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    16d
    Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy (clinicaltrials.gov)
    P3, N=550, Not yet recruiting, Kite, A Gilead Company
    New P3 trial
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV
    18d
    PERSIST: Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials (clinicaltrials.gov)
    P=N/A, N=178, Enrolling by invitation, AvenCell Therapeutics, Inc.
    New trial
    21d
    A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults (clinicaltrials.gov)
    P1, N=18, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P1 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    28d
    A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov)
    P1, N=162, Recruiting, Genentech, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • RG6540 • rimiducid (AP1903)
    1m
    PRO00037171: CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Medical College of Wisconsin | Trial completion date: Jun 2028 --> Feb 2029 | Trial primary completion date: Jun 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    CAR-20/19-T Cells
    1m
    AVC-203-01: QUADvance: Advancing Allogeneic Quad-CAR01-T Therapy in Hard-to-Treat B-Cell Cancers (2025-521735-36-00)
    P1/2, N=60, Recruiting, Avencell Therapeutics Inc.
    New P1/2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    2ms
    C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease (clinicaltrials.gov)
    P1/2, N=24, Not yet recruiting, AbelZeta Inc. | Trial completion date: Dec 2029 --> Jun 2030 | Initiation date: Jan 2026 --> Jul 2026 | Trial primary completion date: Nov 2028 --> May 2029
    Trial completion date • Trial initiation date • Trial primary completion date
    2ms
    A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=3, Completed, Peking University | Recruiting --> Completed | N=18 --> 3
    Trial completion • Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    2ms
    IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy (clinicaltrials.gov)
    P1, N=3, Terminated, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | N=36 --> 3 | Trial completion date: Oct 2026 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> Oct 2025; The collaborating party has adjusted its R&D strategy and terminated the study.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    2ms
    QUADvance: Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=178, Recruiting, AvenCell Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV